Ancient DNA confirms New Mexico tribe's link to famed Chaco Canyon site
The Picuris Pueblo, a sovereign nation in New Mexico, has oral histories and cultural traditions that link the tribe to the region of Chaco Canyon, one of the ancient centers of Pueblo culture and society.
'We've been telling our stories as long as time immemorial,' said Picuris Lt. Gov. Craig Quanchello. But he said those traditions were often "overlooked and erased."
As members of the Picuris Pueblo seek a greater voice in shaping decisions about the future of Chaco Canyon, where debates about oil and gas drilling loom, leaders including Quanchello decided that using DNA sequencing to complement or corroborate their oral histories could be a useful tool. The group began a collaboration with an international team of geneticists.
"The DNA could help us protect" our heritage, he said. "Now we can say, 'This is ours, we need to protect it.'"
The findings, published Thursday in the journal Nature, show close links between the genomes of 13 current members of Picuris and ancient DNA recovered from 16 Picuris individuals who lived between 1300 A.D. and 1500 A.D. in or near Chaco Canyon.
'The results show a strong relationship between ancient and present-day Picuris,' said co-author Thomaz Pinotti, a geneticist at the University of Copenhagen.
The genetic analysis was led by the Picuris. The researchers said this model of collaboration contrasts with a long history of archaeologists and geneticists seizing and studying artifacts and remains without the consent of Indigenous groups.
'It wasn't an easy decision' to begin the collaboration with scientists, said co-author and Picuris Gov. Wayne Yazza. 'This is life-changing data.'
There are 19 Pueblo tribes in New Mexico. The new study does not refute the historic connections of other tribes to Chaco Canyon.
Chaco Culture National Historical Park is a UNESCO World Heritage site managed by the U.S. National Park Service. It is famous for sweeping desert vistas and for monumental sandstone structures — including multistory homes and ceremonial structures — built by ancestral Pueblos.
'It's super important that we don't talk about Chaco in the category of 'lost civilizations,' like the Egyptian pyramids or Stonehenge,' said Paul Reed, a preservation archaeologist at Archaeology Southwest, who was not involved in the study. That notion "is particularly damaging in this instance because it disenfranchises the Pueblo people who live all around the canyon to this day.'
Brian Vallo, a member of the Acoma Pueblo who leads the Chaco Heritage Tribal Association, said a current concern revolves around drilling and mining permits on federal land adjacent to the park, which also impact the environment within the canyon.
'We have these close connections because our ancestors migrated and built these places –- they remain central to the preservation of our own Indigenous culture,' said Vallo, who was not part of the research.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
32 minutes ago
- Business Journals
OSU is harnessing energy from ocean waves to power your home
Seven miles off the Oregon Coast near Newport, Oregon State University has built a unique facility that will help launch a new wave of clean, renewable energy — testing devices that generate electricity from ocean waves at a scale that could support thousands of homes and businesses. PacWave South, which recently finished construction, is a first-of-its-kind test site for wave energy devices in the U.S. More than a decade in the making, PacWave will allow developers to test full-size, utility-scale wave energy devices in real-world conditions. At full capacity, the PacWave site could send up to 20 megawatts of electricity to the local utility grid, enough to power about 2,000 homes. Wave energy, which generates electricity using the motion of ocean waves, remains an untapped but promising renewable energy source. The U.S. Energy Information Administration estimates wave energy could generate as much as 2.64 trillion kilowatt hours, nearly 2/3 of utility-scale electricity generation in the U.S. in 2023. Ocean waves are both powerful and constant, providing a more stable source of energy than wind and solar power. Still, commercial-scale wave energy is about 20 years behind wind. Unlike the familiar three-blade wind turbine, there is not yet an industry standard for capturing and converting wave energy into electricity. That's where PacWave comes in. The site, about two square miles in open water, has four test berths where developers can attach up to 20 wave energy devices of varying designs. The test berths connect to subsea cables, which transmit electricity generated by the devices to an onshore facility where it is conditioned and sent to the local power utility. Oregon is uniquely positioned to lead wave energy development, home to strong, steady waves and a well-established coastal utility infrastructure. Both are critical to testing survivability and reliability in harsh ocean conditions. How much electricity can wave energy devices consistently generate? Can they withstand swells of 20 feet or more from fierce Pacific storms and still send power to the grid? How will devices and cables hold up against corrosion in salt water and the buildup of barnacles, algae and seaweed? PacWave will help developers answer those questions. It is one of the very few wave energy test sites in the world, and with the ability to test full-size, utility-scale wave energy devices connected to the grid, PacWave can most closely replicate commercial applications. In addition, PacWave has already obtained all the necessary state and federal permits, which saves developers time and expense, allowing them to focus on getting their devices in the water. The more than $100 million facility, managed by OSU's Division of Research and Innovation, is supported by funding from the U.S. Department of Energy, the state of Oregon and other public and private entities. Oregon State, which has longstanding relationships with coastal communities and Indigenous tribes through the Hatfield Marine Science Center and OSU Extension Service, conducted years of community outreach during the development of PacWave to build public support. University engineers and ecologists collaborated with the local fishing industry to identify the best location for the site, away from popular commercial and recreational fishing reefs. Also, since PacWave is located seven miles from shore — and because many wave energy devices will be mostly submerged — the site won't be visible from land. Oregon State researchers are monitoring the potential environmental impacts of the PacWave project. Samples taken at PacWave North, a smaller existing test site, have found little impact so far. Researchers will continue to monitor how the wave energy devices, cables and anchors at PacWave South may impact marine life. PacWave provides the infrastructure and expertise to help bring wave energy technologies to market faster and with greater confidence. And OSU researchers have already identified where wave energy could make an immediate impact: Alaska. Many remote coastal communities are not connected to the power grid and must rely on expensive diesel-powered generators. According to PacWave Director Dan Hellin, wave energy devices could provide abundant electricity reliably, at a lower cost and with no carbon emissions. 'There's a huge amount of wave power out there, and PacWave will help us figure out how to harness it effectively and reliably,' Hellin said. 'For wave energy developers looking to prove their designs in real-world conditions, there won't be a better place to test them than at PacWave.' To learn more about PacWave, visit
Yahoo
an hour ago
- Yahoo
Violent supernova spilled a star's ‘guts' before exploding
A completely new supernova variant finally shows a glimpse of a star's innermost 'guts' moments before its destruction. Detailed in a study published August 20 in the journal Nature, their study confirms a longstanding theory about the internal structure of massive stellar objects, and kicks off a host of new questions. Diving into star innards Astronomers have long posited that a star's innards aren't simply a chaotic, roiling ocean of superheated plasma. Instead, they believe they possess layers of chaotic, roiling superheated plasma. In massive stars (those 10 to 100 times larger than the sun) nuclear fusion forces lighter elements in a stellar core to combine into heavier relatives. Over eons, these increasingly dense elements burn away within the core as lighter elements incinerate across successive, encompassing layers. This ultimately results in an incomprehensibly heavy iron core that, once collapsed, initiates a supernova or black hole event. Previously, researchers have documented examples of stripped stars that already lost their helium, exposing stratified, elemental encasements of helium, carbon, and even oxygen. This is usually where such glimpses always ended–until the discovery of SN2021yfj. 'Something very violent must have happened' In 2021, a team led by astrophysicists at Northwestern University utilized the wide-field camera array at the Zwicky Transient Facility (ZTF) near San Diego to scour the evening skies. ZTF's equipment is particularly designed to spot bright, short-lived events like supernovae. In September 2021, researchers noticed just such an occurrence roughly 2.2 billion light-years away. After some assistance from a collaborator at the W.M. Keck Observatory in Hawai'i, they then proceeded to conduct a spectrographic analysis of their supernova discovery, SN2021yfj.'Almost instantly, we realized it was something we had never seen before, so we needed to study it with all available resources,' study co-author and Northwestern University astrophysicist Steve Schulze said in a statement. Schulze and colleagues didn't find the elements they expected (helium, carbon, nitrogen, or oxygen). Instead, their spectrum analysis displayed huge amounts of silicon, sulfur, and argon. These are all heavier elements produced during stellar nuclear fusion near the end of a star's lifespan. 'This star lost most of the material that it produced throughout its lifetime,' explained Schulze. 'So, we could only see the material formed during the months right before its explosion. Something very violent must have happened to cause that.' 'Exotic pathways' to a star's demise That violent something is still a mystery, although researchers have a theory. This gigantic star had literally ripped itself apart from the inside, revealing a cosmic body 'stripped to the bone,' according to Schulze. The team believes that as the core condensed under its own gravitational strength, it became an even denser inferno. At a certain point, it became so hot and dense that it actually reignited a nuclear fusion process so powerful that it generated a huge energy burst. This, in turn, flung away the star's outer layers. Each subsequent 'pair-instability episode' then shed additional elemental layers. 'One of the most recent shell ejections collided with a pre-existing shell, which produced the brilliant emission that we saw as SN2021yfj,' Schulze theorized. However, he stopped short of saying this was the star's definitive cause-of-death. Other possibilities include a pre-supernova eruption, especially strong stellar winds, or even a run-in with an unknown companion star. 'I wouldn't bet my life that it's correct, because we still only have one discovered example,' said Schulze. 'This star really underscores the need to uncover more of these rare supernovae to better understand their nature and how they form.' But according to study co-author Adam Miller, the discovery doesn't mean he and other astrophysicists need to forget everything they know about star life cycles. 'It's not that our textbooks are incorrect, but they clearly do not fully capture everything produced in nature,' he said. 'There must be more exotic pathways for a massive star to end its life that we [haven't] considered.'
Business Wire
4 hours ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
